Navigation Links
Versus Technology, Inc. Announces Expansion of Real-Time Location System to Include Anesthesia Clinic at PeaceHealth RiverBend Campus
Date:1/28/2009

TRAVERSE CITY, Mich., Jan. 28 /PRNewswire-FirstCall/ -- Versus Technology, Inc. today announces a successful implementation and expansion of Enterprise VISion(TM), a wireless real-time location system (RTLS), at the new Sacred Heart Anesthesia Clinic located in Springfield, Oregon. This infrared (IR) and radio-frequency identification (RFID) RTLS accurately tracks patients and equipment, documents patient visit milestones (including interactions with staff), and provides alerts to caregivers to notify staff when the patient is ready for the next stage of care. This automated patient flow improves overall efficiency and coordination of the patient's presurgical visit and allows staff to see more patients by ensuring that patients are seen by the right caregiver at the right time.

The Anesthesia Clinic at RiverBend employs 15 clinical staff and sees over 60 patients per day. Whereas the old clinic was limited to eight rooms and often produced bottlenecks and long waits for patients, the new Anesthesia Clinic has 18 rooms and uses VISion to manage the higher patient volume. Visual representation of patient progression on Enterprise and Floorplan views in the VISion software aids patient flow and provides real-time communication of patient status to caregivers. Questions that are easily answered through VISion and departmental processes include:

    -- Have labs been ordered and if so, have they been drawn?
    -- Has the EKG been completed?
    -- Is the nurse in the room?
    -- Has the nurse completed the assessment?
    -- Is the patient ready to see the anesthesiologist?

Being able "see" their patients and their visit status in the Anesthesia Clinic allows the physicians and anesthesiologists to prepare and adjust their schedules as needed-a benefit that was immediately recognized as the Anesthesia Clinic is physically separated from Sacred Heart Medical Center at RiverBend building.<
'/>"/>

SOURCE Versus Technology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Versus Technology, Inc. Announces Successful Implementation of Automatic Hospital Tracking System at Anne Arundel Medical Center
2. Versus Technology Announces Fiscal Year Results
3. Surprising Results on Smoking Research Hispanic Versus White Female Smokers
4. Versus Technology Announces Third Quarter Results
5. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
6. Eat Well, Save Money: BJs Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices
7. Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model
8. Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006
9. Versus Technology Announces First Quarter Results
10. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
11. Smart Home Cleaning: New Web Site Educates Consumers on Looking Clean Versus Being Clean
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Haemonetics Corporation (NYSE: HAE ) announced ... action to stop Fenwal Inc.,s continued patent infringement ... kits, using a modified separation chamber. Fenwal ... patent and the injunction entered by the Court ... December 1, 2010. According to statements made ...
(Date:12/14/2009)... Calif., Dec. 14 Tough Enough To Wear ... breast cancer, celebrated its fifth anniversary at the ... the Wrangler National Finals Rodeo (Wrangler NFR) in ... with rough-and-tumble rodeo cowboys, the support of the ... the sold-out crowd sported pink shirts, hats, bracelets ...
(Date:12/14/2009)... Staff , ... La Jolla, Calif. (Vocus) -- The ... MD, as the new chief of staff of the 372-bed facility. ... team on Jan. 1, 2010. , , , , ,During his ... Scripps La Jolla’s administrative staff and its board of directors. Dr. ...
(Date:12/14/2009)... Critical to Stemming Tide of Tens of Thousands ... WASHINGTON, Dec. 14 Legislation approved by ... will be crucial in helping to reduce tens ... each year in the United States, the ... The provision was included in the FY ...
(Date:12/14/2009)... Dec. 14 When Kurth Krause, an ... instructions for landing on the moon, he,was confident ... anything.,Years later, Kurth realized there was one thing ... kidney transplant and even though dialysis machines,would keep ... a transplant. Kurth,wrote: "My wife is 69 and ...
Breaking Medicine News(10 mins):Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3
... and post-stem cell transplantation results compared to thalidomide and ... ... Pharmaceuticals,Inc. (Nasdaq: MLNM ) reported the presentation of results from ... randomized,Phase III clinical trial. This study compared VELCADE, thalidomide and,dexamethasone (VcTD) ...
... approved for use as second line therapy for chronic myelogenous ... diagnosed patients in two clinical trials, research teams led by ... Center report at the 49th annual meeting of the American ... trials have a complete cytogenetic response - absence of the ...
... LOS ANGELES, Dec. 9 A federal court ... a harsh spotlight on the pharmaceutical firm,Johnson & ... of,false advertising the controversial chemical sweetener Splenda. United,States ... request for,summary judgment based on that charge that ...
... with high levels of D-dimer face greatest chance of ... Levels of certain blood markers may increase the risk ... relieve symptoms of menopause, new research shows. , ... whether to take the hormone therapy, said the authors ...
... FL, December 8, 2007 A series of studies ... annual meeting elucidates evidence that there is a genetic ... scientific explanation for lower rates of cancer among patients ... rates of smoking and their parents. ...
... arson is a reminder that we must remain vigilant,in ... safety of,the dedicated health care professionals who provide that ... a,statement of Vicki Saporta, President and CEO of the ... Curtis Boyd, MD, in Albuquerque,NM:, As the professional ...
Other Medicine News:Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 2Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 3Health News:Federal Judge Says Sugar Association Suit Accusing Johnson & Johnson of False Advertising to Go Forward 2Health News:Blood Markers Might Predict Clotting Risk With HRT 2Health News:Blood Markers Might Predict Clotting Risk With HRT 3Health News:Studies elucidate genetic links between cancer and schizophrenia 2
(Date:12/14/2009)... 14 In response to an ... in which the Agency recommended that healthcare facilities ... sterile processing system, hospitals throughout the U.S. are ... to that product. According to the FDA, STERIS ... that may affect the safety or the effectiveness ...
(Date:12/14/2009)... -- Following is a statement by Linda A. ... Association (CHPA), regarding today,s release of the National ... survey: ,, "Findings released today on this year,s ... for continued efforts to educate and empower parents ... their teens about medicine abuse. The Consumer Healthcare ...
(Date:12/14/2009)... The board of directors of Eli Lilly ... a dividend for the first quarter of 2010 of ... ,, The dividend is payable March 10, 2010 to ... ,, February 12, 2010. ,, Lilly, a leading ... products by applying the latest research from its own ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 1Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 1Protein handlers should be effective treatment target for cancer and Alzheimers 9501 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 3America Takes on the Challenge to Fight Obesity 53865 1America Takes on the Challenge to Fight Obesity 53865 2America Takes on the Challenge to Fight Obesity 53865 3America Takes on the Challenge to Fight Obesity 53865 4
... lowest dose groups show dose-dependent PSA ... declines to date in all patients - - ... SAN FRANCISCO, Nov. 5 Medivation, Inc.,(Nasdaq: MDVN ) today ... levels of prostate specific,antigen (PSA), a marker of tumor growth, in the ...
... non-responders to previous interferon-based therapy -, - SVR results in ... non- responders, with less frequent dosing -, - ... American Association for the Study of Liver Diseases ... (AASLD) -, ROCKVILLE, Ma., Nov. 5 ...
Other Medicine Technology:Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 2Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 3Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
... This latest sensor array with ... inter-channel spacing of just 2.2 ... is particularly useful when using ... Synthetic Aperture Magnetometry (SAM) or ...
... supine measurement position is achieved using an ... a non-magnetic, mobile patient bed. The patient ... shielded room. In case of an emergency ... the shielded room for e.g. resuscitation purposes. ...
... The Magnes 1300 C is ideal for ... brain and other parts of the body. Often ... its possibilites, including magnetocardiography, gastrointestinal tract, fetal, spinal ... ,The 1300 C, with its 67 detector ...
... one-of-kind portable Digital Radiography system designed for diverse ... a 14 x 17- inch imaging area and ... large imaging area and lightweight design, the CXDI-50G ... Radiography. It is large enough for chest and ...
Medicine Products: